, as were routine laboratory tests. A bone marrow (BM) 6 aspirate and biopsy demonstrated hypocellularity (20%) without dysplasia. Results for BM cytogenetics, fluorescence in situ hybridization (FISH), and a diexpoybutane test for Fanconi anemia were normal. Flow cytometry findings for peripheral blood showed no lymphoproliferative or myeloid-maturation disorder, nor any protein defect consistent with paroxysmal nocturnal hemoglobinuria. Over the next 5 years, the patient remained asymptomatic and transfusion free with stable blood counts and an unchanged BM histology.
/L to 7.6 ϫ 10 9 /L); hemoglobin, 12.9 -14.5 g/dL (reference, 13.0 -17.4 g/dL), with marked macrocytosis (mean corpuscular volume, 105-111 fL; reference, 82.0 -100 fL); and platelets, 46 ϫ 10 9 /L to 71 ϫ 10 9 /L (reference, 140 ϫ 10 9 /L to 440 ϫ 10 9 /L).
DISCUSSION
The patient presented as an adult with moderate AA, which is defined by a hypocellular BM with decreased peripheral blood counts in Ͼ1 cell lineage. Most cases of AA are classified as idiopathic or acquired and are most commonly thought to be due to immune dysregulation, perhaps owing to viral infection. Exposures to a substantial radiation dose, certain drugs, and chemicals, as well as the occurrence of some autoimmune syndromes, have also been associated with marrow failure. Hematologic conditions, including myelodysplasia, paroxysmal nocturnal hemoglobinuria, and, rarely, leukemia can also present as AA. Alternatively, careful evaluation of the patient's history, physical examination, and family history may suggest an inherited BM failure syndrome (IBMFS) as the etiology. This patient demonstrated several features of dyskeratosis congenita (DC) in its classic form (nail dystrophy, mucosal leukoplakia, and skin pigmentation changes) and in concert with other abnormalities, including BM failure, urethral strictures, excessive tear production (epi-phora), premature balding and gray hair, and pulmonary disease (1 ).
PATIENT FOLLOW-UP
On the basis of a presumptive clinical diagnosis of DC, we undertook measurements of telomere length (TL), which showed both his lymphocytes and granulocytes had a markedly reduced (Ͻ1st percentile) median TL (MTL) [4.1 kb vs 7.5 kb (50th percentile for age) and 4.5 kb vs 8.6 kb (50th percentile for age), respectively], thereby confirming the diagnosis (Fig. 1 (3, 4 ) . Telomeres occur at the ends of chromosomes and consist of hundreds to thousands of hexanucleotide repeats [(TTAGGG) n ], which undergo attrition with each cell division. Multiprotein complexes (e.g., including components encoded by TINF2 and CTC1) maintain telomeres, and the ribonucleoprotein telomerase [composed of the products of the TERC, TERT, DKC1, TCAB1 (i.e., WRAP53), NHP2, and NOP10 genes] replaces hexanucleotide repeats by reverse transcription to counteract telomere attrition. The genetic lesions in DC compromise telomere integrity, impairing the self-renewal and regenerative capacity in cells, and presumably explain the premature failure of multiple organs in affected individuals (5 ) .
Defective telomere maintenance is a common feature across DC genotypes that can be exploited for diagnosis. Lansdorp and colleagues have developed a CLIA-certified flow cytometry-based FISH (flow-FISH) approach for quantifying TL in peripheral blood cells (6 ) . Fluorescently labeled peptide nucleic acid probes (CCCTAA) 3 are hybridized to telomeres in permeabilized peripheral blood cells. The number of probes bound to telomeres is proportional to TL, and the total fluorescence intensity of probes bound to all 92 telomere ends of the 46 chromosomes is read out as the MTL per cell. Because telomeres normally shorten 7 Human genes: DKC1, dyskeratosis congenita 1, dyskerin; TINF2, TERF1 (TRF1)-interacting nuclear factor 2; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase; NHP2, NHP2 ribonucleoprotein homolog (yeast); NOP10, NOP10 ribonucleoprotein homolog (yeast); WRAP53 (formerly TCAB1), WD repeat containing, antisense to TP53; CTC1, CTS telomere maintenance complex component 1. (7 ) . Using MTL scores of Ͻ1st percentile ("very low") as a cutoff, Alter et al. showed that flow-FISH provides a sensitivity and a specificity for diagnosing DC of 97% and 91%, respectively, with total lymphocytes, and 97% and 82% with granulocytes. Sensitivity and specificity for diagnosing DC with lymphocyte subsets were investigated, but the best performance characteristics of flow-FISH for a single lineage were obtained from measuring MTL in total lymphocytes. These important studies validated flow-FISH as a test with diagnostic utility for DC, and we used this test to support the clinical diagnosis of DC in this patient (Fig. 1) .
Definitive genetic diagnosis of DC remains limited by the need to sequence a large, yet incomplete set of genes and by the difficulty in establishing the pathogenicity of variant sequences. DKC1 mutations are found in 25%-30% of DC cases. DKC1 is X-linked, and males are affected, whereas female carriers are generally clinically silent. TINF2 mutations account for approximately 15% of DC cases, are autosomal dominant, and are frequently sporadic. TERC and TERT mutations (5%-10% each of all cases) are found in autosomal dominant and recessive DC and show disease anticipation, such that successive generations not only inherit the genetic lesion but also have shorter telomeres, which may produce an earlier onset of clinical manifestations (8 ) . Somatic reversion of the TERC gene, likely driven by a resulting selective growth advantage in hematopoietic stem cells, has been observed in DC and is a potential confounder of genetic testing (9 ) . With sufficient clinical concern, a normal result in a TERC analysis of peripheral blood DNA should be followed by testing of other somatic cells. Our patient's history was insufficient to determine the inheritance pattern, and a combination of CLIAcertified and laboratory-based testing ruled out mutations in DKC1, TINF2, TERC, and TERT. Analysis of the parents' and sibling's MTLs by flow-FISH might clarify the inheritance pattern, and additional candidate gene and exome sequencing might determine the genetic basis of the patient's DC.
Establishing the diagnosis of IBMFS vs acquired AA has significant therapeutic implications. As in this case, delayed and mild presentations must be considered in adults with BM failure. The BM failure of IBMFS generally responds poorly to the cyclosporine A and antithymocyte globulin immunosuppressive regimen used for acquired AA in the absence of a matched sibling donor for hematopoietic cell transplantation (HCT). Moreover, HCT preparative regimens used for AA are associated with unacceptable organ toxicity in DC patients, whereas newer, disease-specific preparative regimens of reduced intensity have yielded improved outcomes. When any IBMFS is suspected, it is imperative to rule out subclinical disease in potential family donors for HCT. After BM failure, the leading causes of death in DC include head, neck, and anogenital squamous cell cancers, pulmonary fibrosis, and cirrhosis (10 ) . Although the pathophysiological relationship of defective telomere integrity to these complications remains speculative, the range of potentially fatal manifestations emphasizes the relevance of family screening, even absent HCT considerations. The diagnosis of DC and other IBMFSs therefore not only has an impact on immediate therapy but also mandates coordinated multidisciplinary care, long-term surveillance, anticipatory guidance, and family and genetic counseling.
POINTS TO REMEMBER
• Aplastic anemia can occur as a consequence of immune dysregulation and toxic exposures, and as a manifestation of several hematologic disorders, including myelodysplasia and IBMFS.
• A genetic cause should be considered in patients of all ages who present with AA. A basic evaluation for DC should include a careful physical examination, medical history, and family history.
• Genetic testing that should be considered in evaluating DC includes measurement of TL in peripheral blood cells and genetic-mutation analysis of candidate genes.
• Although DC is caused by lesions in several genes known to compromise telomere maintenance, the responsible gene(s) remain unknown in 50% of cases.
• Establishing a diagnosis of DC vs idiopathic AA has major implications for the patient and the family.
